Summary & Overview

Amputation of Lower Limb for Endocrine, Nutritional and Metabolic Disorders with MCC: Inpatient Reimbursement Overview

DRG 616 addresses inpatient admissions for lower limb amputation associated with endocrine, nutritional, and metabolic disorders when a Major Complication or Comorbidity is present, encompassing cases such as amputation for advanced diabetic complications. Correct classification matters for inpatient reimbursement because the Major Complication or Comorbidity status increases resource intensity and influences Medicare payment.

DRG Amputation of Lower Limb for Endocrine, Nutritional and Metabolic Disorders with MCCDRG 616Diagnosis-Related GroupInpatient ReimbursementMedicareAmputationEndocrinologyVascular SurgeryDiabetesHospital Coding

DRG 616 Overview

DRG 616 covers inpatient hospital admissions for lower limb amputation procedures performed in the setting of underlying endocrine, nutritional, and metabolic disorders when a Major Complication or Comorbidity is present. Typical cases include amputations related to advanced diabetic foot disease, severe peripheral vascular compromise, or metabolic complications that increase clinical complexity. This Diagnosis-Related Group is important for Medicare payment because the presence of a Major Complication or Comorbidity increases relative resource use and affects the hospital reimbursement weight. Hospitals and coders must accurately document operative procedures and the qualifying comorbid conditions to align clinical care with appropriate Medicare Severity Diagnosis-Related Group assignment.

Clinical Trials

Acute perioperative studies evaluating strategies to reduce surgical site infection, stump healing complications, and immediate postoperative mortality in patients undergoing lower limb amputation for diabetic or metabolic limb ischemia. These trials enroll high-risk inpatients with severe peripheral arterial disease, diabetic foot infection, or critical limb ischemia undergoing major amputation and compare interventions such as optimized perioperative glycemic control protocols, antibiotic regimens, or wound care bundles. Results are directly relevant to hospital providers and payers because reducing early complications shortens length of stay, lowers readmission risk, and decreases high-cost resource utilization tied to this DRG.
Comparative effectiveness studies examining different levels of amputation and limb-sparing versus amputation approaches in patients with endocrine, nutritional or metabolic disease–related limb loss. These observational cohorts or pragmatic randomized studies focus on functional outcomes, prosthetic suitability, complication rates, and long-term survival among patients with diabetes, renal disease, or peripheral neuropathy to determine which surgical choice yields better mobility and lower overall costs. Findings inform surgical decision-making, discharge planning, and payer coverage policies by linking index procedure choice to downstream rehabilitation needs, prosthesis costs, and recurrent hospitalization rates.
Post-discharge longitudinal outcomes and care-coordination trials aimed at reducing readmissions and improving rehabilitation and prosthetic access for survivors of major lower limb amputation due to metabolic disease. These studies test case-management models, home-based wound surveillance, telehealth follow-up, and integrated vascular/diabetes clinics in the months after discharge for patients with multiple comorbidities and high social needs. For providers and payers, evidence from these trials supports interventions that improve functional recovery and quality of life while potentially lowering readmission and long-term care costs associated with this DRG.

Related Codes

637-DIABETES-WITH-MCC

Diabetes with Major Complication or Comorbidity: Inpatient Reimbursement Overview

643-ENDOCRINE-DISORDERS-WITH-MCC

Endocrine Disorders with MCC: Inpatient Reimbursement Overview

640-MISCELLANEOUS-DISORDERS-OF-NUTRITION-METABOLISM-FLUIDS-AND-ELECTROLYTES-WITH-MCC

Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes with MCC: Inpatient Reimbursement Overview

614-ADRENAL-AND-PITUITARY-PROCEDURES-WITH-CC-MCC

Adrenal and Pituitary Procedures with CC/MCC: Inpatient Reimbursement Overview

628-OTHER-ENDOCRINE-NUTRITIONAL-AND-METABOLIC-O-R-PROCEDURES-WITH-MCC

Other Endocrine, Nutritional and Metabolic O.R. Procedures with MCC: Inpatient Reimbursement Overview

619-O-R-PROCEDURES-FOR-OBESITY-WITH-MCC

O.R. Procedures for Obesity with MCC: Inpatient Reimbursement Overview

641-MISCELLANEOUS-DISORDERS-OF-NUTRITION-METABOLISM-FLUIDS-AND-ELECTROLYTES-WITHOUT-MCC

Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes without MCC: Inpatient Reimbursement Overview

626-THYROID-PARATHYROID-AND-THYROGLOSSAL-PROCEDURES-WITH-CC

Thyroid, Parathyroid and Thyroglossal Procedures with CC: Inpatient Reimbursement Overview

618-AMPUTATION-OF-LOWER-LIMB-FOR-ENDOCRINE-NUTRITIONAL-AND-METABOLIC-DISORDERS-WITHOUT-CC-MCC

Amputation of Lower Limb for Endocrine, Nutritional and Metabolic Disorders without CC/MCC: Inpatient Reimbursement Overview

624-SKIN-GRAFTS-AND-WOUND-DEBRIDEMENT-FOR-ENDOCRINE-NUTRITIONAL-AND-METABOLIC-DISORDERS-WITHOUT-CC-MCC

Skin Grafts and Wound Debridement for Endocrine, Nutritional and Metabolic Disorders without CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 25

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.